Exact Sciences, Humana Expand Colorectal Cancer Screening Collaboration

The Cologuard Plus test is now available to eligible Humana Medicare Advantage members, thanks to an augmented partnership between Exact Sciences Corp. and Humana Inc. The fourth largest U.S. private insurer, Humana has approximately 5.8 million Medicare Advantage members.

“The Exact Sciences team is proud to expand access to Cologuard Plus through our collaboration with Humana, making it easier for more people to access this revolutionary, non-invasive colorectal cancer screening test from the comfort of home,” said Jake Orville, executive vice president and general manager, Screening, at Exact Sciences. “This agreement reflects our shared commitment to removing barriers for patients and advancing earlier detection, when treatment is most effective.”

Launched in March 2025, Cologuard Plus has been approved by the U.S. Food and Drug Administration (FDA), granted Medicare coverage, and included in the U.S. Preventive Services Task Force guidelines.

Developed in collaboration with Mayo Clinic, the Cologuard and Cologuard Plus tests are first-line, noninvasive colorectal cancer (CRC) screening options for adults aged 45 or older who are at average risk for the disease. The Cologuard test changed CRC screening by detecting specific DNA markers and blood in stool associated with cancer and precancer, allowing patients to complete the collection kit at home without special preparation or time off, and return the kit to the lab for results. It is included in national screening guidelines from the American Cancer Society (2018) and the U.S. Preventive Services Task Force (2021). Since its inception in 2014, Cologuard has been used to screen for CRC more than 20 million times.   The Cologuard test and Cologuard Plus test are only available in the United States. 
 
Building on this success, the FDA-approved Cologuard Plus test raises the performance bar even further and features novel biomarkers, improved laboratory processes, and enhanced sample stability. The Cologuard Plus test is expected to reduce false positives by more than 40% compared to the original Cologuard test, helping minimize unnecessary follow-up colonoscopies. Both tests demonstrate Exact Sciences’ commitment to improving CRC screening access and outcomes.   

A provider of cancer screening and diagnostic tests, Exact Sciences helps patients and healthcare providers make timely, informed decisions before, during, and after a cancer diagnosis. The company’s growing portfolio includes well-established brands such as Cologuard and Oncotype DX, along with solutions like Oncodetect for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a pipeline of advanced cancer diagnostics aimed at improving outcomes.